Carnegie acted as joint bookrunner in the private placement of NOK 145 million in new equity by SpinChip Diagnostics.
Representing the future of point-of-care testing, SpinChip Diagnostics was founded in Norway in 2012. SpinChip’s proprietary platform is focused on in vitro diagnostics (IVD) to develop diagnostic tests for acute and chronic cardiac indications where test results are rapidly needed to provide patients with life-saving treatments.